The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
Findings show accumulation of neuronal injury and functional decline suggesting that changes in gonadal hormones may be associated with changes in functional and biological markers in MS.
People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...
GlobalData on MSN4d
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis casesTeva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...
The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...
Earlier studies indicated that COVID infection might cause MS symptoms to worsen, particularly if the symptoms coincide with those associated with long COVID. For this new study, researchers tracked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback